Christopher Krawtschuk is CFO at bluebird bio, Inc. (BLUE). They have made 1 open-market trade across 1 company since 2023, most recently 2023-12-06.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BLUE | 45,474 | $226K |
Shares reported on the most recent Form 4, priced at the 2023-12-08 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BLUE | SELL | 2023-12-06 | 2023-12-08 | $4.52 | $20K | -54.9% | -49.8% | -50.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.